mitomycin has been researched along with Metastase in 220 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 9.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer." | 9.11 | Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. ( Alland, L; Erazo, A; Georgoulias, VA; Henderson, IC; Kaufmann, M; Keller, AM; Lluch, A; Mellars, L; Mennel, RG; Nabholtz, JM; Tendler, C; Vogel, CL; von Minckwitz, G, 2004) |
| "This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy." | 9.11 | Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. ( Archer, CD; Assersohn, LA; Gregory, RK; Johnston, SR; Mendes, R; Smith, IE; Urruticoechea, A; Verrill, M; Walsh, G, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Both mitomycin C combination regimens seem to provide an acceptable therapeutic index in patients with fluoropyrimidine/leucovorin-pretreated metastatic colorectal cancer." | 9.10 | Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | 9.08 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 9.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 9.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 9.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle." | 9.07 | Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994) |
| "In February 1986 we began a study to test the activity of mitomycin C (12 mg/m2) plus vinblastine (6 mg/m2) on day 1 of a 28-day cycle (MV) as second or third-line chemotherapy for metastatic breast cancer patients." | 9.07 | Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gridelli, C; Nuzzo, F; Pagliarulo, C; Perrone, F; Ruggiero, A, 1993) |
| "The efficacy and toxicity of navelbine 30 mg/m2 administered intravenously (IV) over 30 minutes every 3 weeks, and mitomycin C 15 mg/m2 administered IV every 6 weeks was assessed in 34 patients with metastatic breast cancer refractory to first-line chemotherapy." | 9.07 | Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. ( Depisch, D; Haider, K; Kornek, G; Kwasny, W; Pirker, R; Scheithauer, W; Schenk, T, 1993) |
| "Seventy-six women with previously treated breast cancer were randomized to receive mitomycin (M) or M plus high-dose oral medroxyprogesterone acetate (MMPA)." | 9.07 | A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. ( Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC, 1993) |
| "64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy." | 9.06 | Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. ( Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 9.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer." | 8.86 | Is there a role for mitomycin C in metastatic colorectal cancer? ( Dimou, A; Saif, MW; Syrigos, KN, 2010) |
| "The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine." | 7.83 | Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. ( Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG, 2016) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 7.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "The purpose of our study was to retrospectively evaluate the feasibility, toxicity and impact on overall (OS) and disease-free (DFS) survival of intra-arterial liver perfusion with mitomycin-C (MMC) [hypoxic liver perfusion with MMC (HLPM)] in patients with multifocal liver metastases or with unresectable primary liver tumours." | 7.77 | Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients. ( Baggiani, A; Bagliani, A; Belli, L; Belloni, P; Bregni, M; Campagnoli, E; Caspani, B; Crocchiolo, R; Ierardi, AM; Motta, F; Setola, E; Tempini, S; Toniolo, D, 2011) |
| "A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer." | 7.68 | Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. ( D'Alessandro, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A, 1991) |
| "Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i." | 7.67 | Etoposide and mitomycin-C in pretreated metastatic breast cancer. ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989) |
| "Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active." | 7.67 | Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. ( Dees, A; Stoter, G; van Putten, WL; Verweij, J, 1987) |
| "Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks." | 7.67 | Mitomycin C and vinblastine in the treatment of advanced breast cancer. ( Knight, RK; Radford, JA; Rubens, RD, 1985) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | 7.66 | [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin." | 7.66 | Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report. ( Oster, MW; Park, Y, 1983) |
| "Overall, 77." | 6.72 | Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | 6.70 | Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| "Although hepatic metastases were detected, total gastrectomy was initially performed for hemorrhage control." | 5.40 | [A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy]. ( Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T, 2014) |
| "Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)." | 5.35 | Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | 5.27 | Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 5.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy." | 5.22 | Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer." | 5.11 | A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. ( Frödin, JE; Glimelius, B; Gyldenkerne, N; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E, 2004) |
| "To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer." | 5.11 | Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. ( Alland, L; Erazo, A; Georgoulias, VA; Henderson, IC; Kaufmann, M; Keller, AM; Lluch, A; Mellars, L; Mennel, RG; Nabholtz, JM; Tendler, C; Vogel, CL; von Minckwitz, G, 2004) |
| "This phase II study assessed the clinical efficacy and tolerability of a combination of mitomycin C, vinblastine and cisplatin in patients with metastatic breast cancer (MBC) previously treated with chemotherapy." | 5.11 | Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. ( Archer, CD; Assersohn, LA; Gregory, RK; Johnston, SR; Mendes, R; Smith, IE; Urruticoechea, A; Verrill, M; Walsh, G, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Both mitomycin C combination regimens seem to provide an acceptable therapeutic index in patients with fluoropyrimidine/leucovorin-pretreated metastatic colorectal cancer." | 5.10 | Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer." | 5.09 | Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000) |
| "Patients with metastatic breast cancer were randomly assigned to receive as second-line chemotherapy either MMM (mitomycin 8 mg/m2 day 1; mitoxantrone 8 mg/m2 days 1 and 22; methotrexate 35 mg/m2 days 1 and 22) alone or in combination with filgrastim (5 micrograms/kg s." | 5.08 | Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. ( Blomqvist, C; Jantunen, I; Kellokumpu-Lehtinen, P; Maiche, A; Muhonen, T; Pertovaara, H; Pyrhönen, S; Voutilainen, L, 1996) |
| "Between 1985 and 1988, the effect of using ftorafur (FT) or PSK (an immunotherapy agent) in combination with the conventional postoperative adjuvant therapy using mitomycin (MMC) plus tamoxifen (TAM) was assessed in stage II, oestrogen receptor-positive (ER+) breast cancer patients." | 5.08 | Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can ( Dohi, K; Monden, Y; Morimoto, T; Nomura, Y; Ogawa, M; Ogawa, N; Orita, K; Sugimachi, K; Toge, T, 1996) |
| "Mitomycin C (MMC)-vinblastine (VBL) is a regimen that has commonly been used as salvage therapy for advanced breast cancer for many years." | 5.08 | Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). ( Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 5.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 5.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle." | 5.07 | Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Del Mastro, L; Gravina, A; Gridelli, C; Pagliarulo, C; Perrone, F, 1994) |
| "In February 1986 we began a study to test the activity of mitomycin C (12 mg/m2) plus vinblastine (6 mg/m2) on day 1 of a 28-day cycle (MV) as second or third-line chemotherapy for metastatic breast cancer patients." | 5.07 | Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. ( Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gridelli, C; Nuzzo, F; Pagliarulo, C; Perrone, F; Ruggiero, A, 1993) |
| "The efficacy and toxicity of navelbine 30 mg/m2 administered intravenously (IV) over 30 minutes every 3 weeks, and mitomycin C 15 mg/m2 administered IV every 6 weeks was assessed in 34 patients with metastatic breast cancer refractory to first-line chemotherapy." | 5.07 | Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. ( Depisch, D; Haider, K; Kornek, G; Kwasny, W; Pirker, R; Scheithauer, W; Schenk, T, 1993) |
| "Seventy-six women with previously treated breast cancer were randomized to receive mitomycin (M) or M plus high-dose oral medroxyprogesterone acetate (MMPA)." | 5.07 | A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer. ( Falkson, CB; Falkson, CI; Falkson, G; Falkson, HC, 1993) |
| "64 eligible women with previously treated metastatic breast cancer received mitomycin C plus vindesine chemotherapy." | 5.06 | Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. ( Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 5.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "The Georgetown University Hospital experience in the treatment of advanced breast cancer using either a combination of doxorubicin (adriamycin) and vincristine (AV) or adriamycin and mitomycin-C (AM) is presented." | 5.05 | Treatment of advanced breast cancer with two doxorubicin-containing regimens. ( Byrne, PJ; Harris, MA; Oishi, S; Schein, PS; Schlesinger, C; Smith, FP; Ueno, W, 1984) |
| "An overview of the clinical trials where mitomycin has been used in combination with modern compounds in the various settings of metastatic colorectal cancer." | 4.86 | Is there a role for mitomycin C in metastatic colorectal cancer? ( Dimou, A; Saif, MW; Syrigos, KN, 2010) |
| " Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer." | 4.80 | [Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998) |
| "The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine." | 3.83 | Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline. ( Almstedt, K; Bayer, CM; Beckmann, MW; Fasching, PA; Hack, CC; Hein, A; Jud, SM; Lux, MP; Rack, B; Rauh, C; Scharl, A; Schrauder, MG, 2016) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 3.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "The purpose of our study was to retrospectively evaluate the feasibility, toxicity and impact on overall (OS) and disease-free (DFS) survival of intra-arterial liver perfusion with mitomycin-C (MMC) [hypoxic liver perfusion with MMC (HLPM)] in patients with multifocal liver metastases or with unresectable primary liver tumours." | 3.77 | Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients. ( Baggiani, A; Bagliani, A; Belli, L; Belloni, P; Bregni, M; Campagnoli, E; Caspani, B; Crocchiolo, R; Ierardi, AM; Motta, F; Setola, E; Tempini, S; Toniolo, D, 2011) |
| "A significant reduction in tumor implantation and port-site metastases was observed in all treatment groups (specific oligopeptides and mitomycin)." | 3.74 | Inhibition of tumor implantation after laparoscopy by specific oligopeptides: a novel approach to adjuvant intraperitoneal therapy to prevent tumor implantation in an animal model. ( Fornara, P; Jurczok, A; Schneider, A, 2007) |
| " Nitrotriazole chemosensitizer in ultralow doses increased the sensitivity of leukemia P388/rn substrain with multiple drug resistance phenotype to mitomycin C during combination therapy." | 3.72 | Ultralow doses of various drugs in chemotherapy of experimental tumors. ( Konovalova, NP, 2003) |
| "A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer." | 3.68 | Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. ( D'Alessandro, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A, 1991) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "Twenty-five patients with metastatic breast cancer in progression after prior chemotherapy +/- hormonotherapy were treated with etoposide 50 mg/m2 i." | 3.67 | Etoposide and mitomycin-C in pretreated metastatic breast cancer. ( Cellerino, R; Menichetti, ET; Miseria, S; Silva, RR; Torresi, U; Tummarello, D, 1989) |
| "Of 299 patients who presented with superficial bladder cancer (Ta, T1), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C)." | 3.67 | Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. ( Chisholm, GD; Elton, RA; Hargreave, TB; Newsam, JE; Smith, G, 1986) |
| "Mitomycin C (MMC) is rarely used in first-line chemotherapy for advanced breast cancer, although the drug is reported to be active." | 3.67 | Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. ( Dees, A; Stoter, G; van Putten, WL; Verweij, J, 1987) |
| "Forty-six patients with recurrent metastatic breast cancer were treated with a combination chemotherapy including doxorubicin and mitomycin C." | 3.67 | Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. ( Brambilla, MC; Comazzi, R; Genitoni, V; Guindani, A; Lacaita, G; Villani, F; Volonterio, A, 1985) |
| "Forty-nine women with progressive metastatic breast cancer, extensively pretreated, received mitomycin C 12 mg/m2 and vinblastine 6 mg/m2 intravenously every 3 weeks." | 3.67 | Mitomycin C and vinblastine in the treatment of advanced breast cancer. ( Knight, RK; Radford, JA; Rubens, RD, 1985) |
| " A complete regression of pleural, pulmonary parenchymal, cutaneous, and bone metastases was seen following therapy with 5-fluorouracil, Adriamycin, and mitomycin C." | 3.66 | Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy. ( Budd, GT; Groppe, CW, 1983) |
| "Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV)." | 3.66 | [Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin]. ( Hamada, Y; Kanda, K; Nomura, Y; Saeki, K; Tashiro, H, 1983) |
| "Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate." | 3.66 | [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983) |
| "Fifteen patients with metastatic breast cancer previously treated with chemotherapy were treated with a regimen consisting of vincristine, Adriamycin, and mitomycin." | 3.66 | Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report. ( Oster, MW; Park, Y, 1983) |
| "The incidence of liver metastasis in group A was 34% which was lower than 50% in group B." | 2.74 | Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| "Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient." | 2.73 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008) |
| "Overall, 77." | 2.72 | Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006) |
| "Only 1-year metastasis in the WCA group was 15." | 2.71 | [Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an]. ( Shen, KP; Yang, JK; Zhen, J, 2003) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "Two hundred ten patients with primary breast cancer (T1-T4, N0, N1-2) were randomised to receive treatment with neoadjuvant chemoendocrine therapy or conventional post-operative chemoendocrine therapy." | 2.70 | Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. ( Coombes, RC; Ford, HT; Gazet, JC; Gray, R; Lowndes, S; Makinde, V; McConkey, C; Quilliam, J; Sutcliffe, R, 2001) |
| "Liver metastasis was the only significant variable in the best subset regression model that predicted good response to MAP (CR and good PR) (P = 0." | 2.69 | Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. ( Hong, RL; Hsu, MM; Ko, JY; Sheen, TS; Ting, LL; Wang, CC, 1999) |
| "This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer." | 2.69 | Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. ( Benter, T; Dörken, B; Hohenberger, P; Köhne, CH; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2000) |
| " Interim analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchidectomy alone (P = ." | 2.68 | Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer. ( Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; Van Poppel, H; Vandenbroucke, F; Vanuytsel, L, 1995) |
| "Vascular invasion and intrahepatic metastasis by hepatocellular carcinoma are important factors predisposing to tumor recurrence." | 2.67 | Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. ( Ii, T; Iyobe, T; Izumi, R; Matsui, O; Miyazaki, I; Nonomura, A; Shimizu, K; Yagi, M, 1994) |
| "Mitomycin C was used as the anticancer drug and given at the dose of 8mg/m2 per time." | 2.67 | [Comparative clinical study in metastatic liver cancer between intra-arterial infusion of mitomycin C alone and intra-arterial infusion of mitomycin C combined with PJ-203 (degradable starch microspheres)]. ( Kondo, M; Nakamura, H; Ogawa, N; Okawa, T; Taguchi, T; Tanikawa, K, 1993) |
| "Mitomycin C was given at a fixed dose of 20 mg/m2 at the end of the BW12C infusion." | 2.67 | Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer. ( Bleehen, NM; Dennis, IF; Ramsay, JR; Workman, P, 1993) |
| " Preliminary analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchiectomy alone (p = 0." | 2.67 | Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial. ( Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; van den Broucke, F; Van Poppel, H; van Uytsel, L, 1993) |
| "Transperitoneal and lymph node metastases were the major causes of treatment failure." | 2.66 | Gastric cancer: overview of current therapies. ( Douglass, HO, 1985) |
| "Although hepatic metastases were detected, total gastrectomy was initially performed for hemorrhage control." | 1.40 | [A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy]. ( Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T, 2014) |
| "Patients had different sources of liver metastasis." | 1.38 | Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. ( Akhlaghpoor, S; Amoui, M; Aziz-Ahari, A; Poorbeigi, H; Sheybani, S; Tolooee, S, 2012) |
| "Among 148 breast cancer samples analyzed by MLPA, four samples harbored intragenic deletions/duplications: Thus, exons 1-2 were deleted in two tumors and exons 21-23 in one tumor, while one sample harbored duplication of exons 18-23." | 1.37 | Alterations of the retinoblastoma gene in metastatic breast cancer. ( Berge, EO; Knappskog, S; Lillehaug, JR; Lønning, PE, 2011) |
| "For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0." | 1.35 | Platinum-based chemotherapy in triple-negative breast cancer. ( Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G, 2008) |
| "Finally, the growth and metastasis of KGN cells injected subcutaneously (s." | 1.35 | Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line. ( Imai, M; Muraki, M; Saito, H; Seiki, M; Takahashi, Y; Takamatsu, K, 2008) |
| "Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC)." | 1.35 | Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. ( Hatake, K; Ito, Y; Iwase, T; Miura, H; Seto, Y; Sugihara, T; Takahashi, S; Tanabe, M; Tokudome, N, 2009) |
| "Generalized metastases showed substantial progression." | 1.32 | Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome. ( Bonnekoh, B; Franke, I; Gollnick, H; Grundmann, JU; Weisshaar, E, 2003) |
| "Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma." | 1.31 | Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. ( Fujii, M; Igarashi, N; Kameyama, K; Kimata, M; Kitajima, M; Kubota, T; Kumai, K; Okada, Y; Otani, Y; Wada, N; Yokoyama, T; Yoshimizu, N, 2002) |
| "IHCP combined with aggressive surgery was performed in 48 gastric carcinoma patients with peritoneal carcinomatosis; 18 gastric carcinoma patients with peritoneal carcinomatosis serving as controls were treated with surgery alone." | 1.30 | Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. ( Fujimoto, S; Isawa, E; Kobayashi, K; Mutou, T; Ohkubo, H; Sumida, M; Takahashi, M; Toyosawa, T, 1997) |
| "The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR." | 1.29 | Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995) |
| "Pancreatic cancer is a disease with essentially no effective treatment." | 1.29 | A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993) |
| "We have investigated the therapeutic effect of CH-271 fusion polypeptide containing both cell-binding domain (C-274) and heparin-binding domain (H-271) of fibronectin in combination with anticancer drugs such as doxorubicin (DOX) or mitomycin C (MMC) on tumor metastasis of different types of tumors." | 1.29 | Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. ( Azuma, I; Igarashi, Y; Ishizaki, Y; Kato, I; Kobayashi, H; Komazawa, H; Saiki, I; Yoneda, J, 1993) |
| "Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix." | 1.29 | Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996) |
| "SPG also inhibited the pulmonary metastasis of NR-S1 tumor after radiotherapy." | 1.28 | Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice. ( Amemiya, K; Arika, T; Nomoto, K, 1992) |
| "Tegafur p." | 1.28 | Alternating chemotherapy in advanced gastric cancer. A phase II study. ( Barón-Saura, JM; Berrocal, A; Feliu, J; Girón, CG; González-Baron, M, 1991) |
| "For seventy two patients with liver metastasis, radical surgery with removal of liver metastatic lesions post removed intra arterial infusion therapy (5FU,MMC) was carried out and the resulting 5-year survival rate was 40% for patients with H1 liver metastasis." | 1.28 | [Surgery for far-advanced colorectal cancer--extension of surgical indication and its results]. ( Hojo, K, 1989) |
| " On the other hand, results from isolated limb perfusion for satellitosis and in-transit metastasis suggest distinct dose-response correlations with tumoricidal properties of appropriate antineoplastic agents." | 1.28 | [Systemically administered regional tumor therapy. Regional hemi-body chemotherapy of metastatic malignant melanoma--an experimental therapy concept]. ( Aigner, KR; Link, KH; Müller, H; Voigt, H; Walther, H, 1989) |
| "Twelve of the patients had primary hepatocellular carcinoma and six had metastatic liver carcinoma originating from an unknown primary site." | 1.27 | Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. ( Benjamin, RS; Chuang, VP; Fuqua, R; Mavligit, GM; Patt, YZ; Wallace, S, 1983) |
| "Fifty-seven patients with metastatic breast carcinoma have been treated with mitomycin C (10 mg/m2 IV 6-weekly), melphalan (6 mg/m2 PO X 3 days, 3-weekly), and methotrexate (35 mg/m2 IV 3-weekly) to assess the efficacy and toxicity of this regimen." | 1.27 | Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Perez, DJ; Powles, TJ, 1984) |
| "Especially in liver metastasis of the breast cancer, MMC-m." | 1.27 | [Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer]. ( Itoh, J; Katoh, T; Nakagawa, H; Sasaki, H; Takahashi, T, 1983) |
| "Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent." | 1.27 | Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983) |
| "She died from general metastasis seven months after the radical mastectomy in spite of adjuvant immunochemotherapy." | 1.27 | [A case of bilateral metastatic breast carcinoma from gastric carcinoma]. ( Hanamura, N; Iida, F; Kasuga, Y; Katsuyama, T; Oota, H; Senga, O; Tsuchiya, S, 1986) |
| " Based on the observed objective tumor response rate and median patient survival, further studies of these drugs in combination for the treatment of advanced gastric cancer are indicated." | 1.27 | Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer. ( Hahn, RG; Moertel, CG; O'Connell, MJ; Schutt, AJ, 1987) |
| "In the amputation system of the same metastasis model at a dose of 4 mg/kg/d i." | 1.27 | A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix. ( Hamanaka, T; Kawahara, K; Ohgoshi, M; Tsukagoshi, S; Tsuruo, T; Yamakawa, K, 1987) |
| "Three metastatic variants, BL6 (high metastasis), F1 (nonmalignant) and F10 (intermediate malignancy) of the B16 murine melanoma, and a pulmonary metastatic line BL6-ML8 of the BL6 primary tumour have been examined for spontaneous sister chromatid exchange (SCE)." | 1.27 | Spontaneous sister chromatid exchange in metastatic variants of the murine B16 melanoma and human astrocytomas in culture. ( Hunt, G; Lakshmi, MS; Sherbet, GV, 1988) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 1.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "The dominant location of metastasis was the liver in 21 pts (48." | 1.27 | Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM). ( Amadori, D; Amadori, M; Biserni, R; Bonaguri, C; Faedi, M; Gentilini, P; Ravaioli, A; Ridolfi, R, 1986) |
| "After treatment, the incidence of lung metastasis was analyzed in LLC-inoculated mice, and the presence or absence of metastasis in affiliated lymph nodes was determined in mouse ascites hepatoma 134-inoculated mice." | 1.27 | Effects of total-body hyperthermia on metastases from experimental mouse tumors. ( Koga, S; Maeta, M; Oda, M, 1985) |
| "Nine patients with advanced cervical cancer were treated with a combination chemotherapy (MVP) consisting of mitomycin C 8 mg/m2 i." | 1.27 | [A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (40.91) | 18.7374 |
| 1990's | 60 (27.27) | 18.2507 |
| 2000's | 44 (20.00) | 29.6817 |
| 2010's | 23 (10.45) | 24.3611 |
| 2020's | 3 (1.36) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, MS | 1 |
| Johnson, P | 1 |
| Romanes, JP | 1 |
| Freitag, HE | 1 |
| Spring, ME | 1 |
| Garcia-Henriquez, N | 1 |
| Monson, JRT | 1 |
| Woeste, MR | 1 |
| Philips, P | 1 |
| Egger, ME | 1 |
| Scoggins, CR | 1 |
| McMasters, KM | 1 |
| Martin, RCG | 1 |
| Chen, L | 1 |
| Chen, Q | 1 |
| Wu, Y | 1 |
| Zhu, M | 1 |
| Hu, J | 1 |
| Zhuang, Z | 1 |
| Moiseenko, AV | 1 |
| Polikarpov, AA | 1 |
| Tarazov, PG | 1 |
| Korovina, YV | 1 |
| Rozengauz, EV | 1 |
| Shelkoplyas, EN | 1 |
| Granov, DA | 1 |
| Saif, MW | 2 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Ozdemir, O | 1 |
| Ozdemir, P | 1 |
| Veral, A | 1 |
| Uluer, H | 1 |
| Ozhan, MH | 1 |
| Ueda, A | 1 |
| Hosokawa, A | 1 |
| Ogawa, K | 1 |
| Yoshita, H | 1 |
| Mihara, H | 1 |
| Ando, T | 1 |
| Kajiura, S | 1 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Terada, M | 1 |
| Kobayashi, T | 2 |
| Horikawa, N | 1 |
| Yabushita, K | 1 |
| Note, M | 1 |
| Sugiyama, T | 1 |
| Miyakawa, A | 1 |
| Ishibashi, H | 2 |
| Takashina, A | 1 |
| Ishigaki, K | 1 |
| Iwai, Y | 1 |
| Abe, H | 1 |
| Katagiri, T | 1 |
| Sakaguchi, Y | 1 |
| Matsushima, T | 1 |
| Tamura, T | 1 |
| Komata, S | 1 |
| Kubota, M | 1 |
| Suzuki, Y | 1 |
| Nakamura, A | 1 |
| Itobayashi, E | 1 |
| Shimura, H | 1 |
| Shimura, K | 1 |
| Okuno, S | 1 |
| Petersen, I | 1 |
| Shives, T | 1 |
| Mahoney, M | 1 |
| Haddock, M | 1 |
| Sim, F | 1 |
| O'Connor, MI | 1 |
| Markovic, SN | 1 |
| Maples, W | 1 |
| Miranda, MB | 1 |
| Hartmann, JT | 2 |
| Al-Batran, SE | 2 |
| Kripp, M | 1 |
| Gencer, D | 1 |
| Hochhaus, A | 1 |
| Hofheinz, RD | 1 |
| Merx, K | 1 |
| Bozkurt, O | 1 |
| Karaca, H | 1 |
| Ciltas, A | 1 |
| Kaplan, MA | 1 |
| Benekli, M | 1 |
| Sevinc, A | 1 |
| Demirci, U | 1 |
| Eren, T | 1 |
| Kodaz, H | 1 |
| Isikdogan, A | 1 |
| Ozkan, M | 1 |
| Buyukberber, S | 1 |
| Stec, R | 1 |
| Bodnar, L | 1 |
| Smoter, M | 1 |
| Korniluk, J | 1 |
| Kuchar, A | 1 |
| Młot, B | 1 |
| Szczylik, C | 1 |
| Weickhardt, AJ | 1 |
| Williams, DS | 1 |
| Lee, CK | 1 |
| Chionh, F | 1 |
| Simes, J | 1 |
| Murone, C | 1 |
| Wilson, K | 2 |
| Parry, MM | 1 |
| Asadi, K | 1 |
| Scott, AM | 1 |
| Punt, CJ | 1 |
| Nagtegaal, ID | 1 |
| Price, TJ | 2 |
| Mariadason, JM | 1 |
| Tebbutt, NC | 2 |
| Schneider, CC | 1 |
| Archid, R | 1 |
| Fischer, N | 1 |
| Bühler, S | 1 |
| Venturelli, S | 1 |
| Berger, A | 1 |
| Burkard, M | 1 |
| Kirschniak, A | 1 |
| Bachmann, R | 1 |
| Königsrainer, A | 1 |
| Glatzle, J | 1 |
| Zieker, D | 1 |
| Belgioia, L | 1 |
| Vagge, S | 1 |
| Agnese, D | 1 |
| Garelli, S | 1 |
| Murialdo, R | 1 |
| Fornarini, G | 1 |
| Chiara, S | 1 |
| Gallo, F | 1 |
| Bacigalupo, A | 1 |
| Corvò, R | 1 |
| Almstedt, K | 1 |
| Fasching, PA | 1 |
| Scharl, A | 1 |
| Rauh, C | 1 |
| Rack, B | 1 |
| Hein, A | 1 |
| Hack, CC | 1 |
| Bayer, CM | 1 |
| Jud, SM | 1 |
| Schrauder, MG | 1 |
| Beckmann, MW | 1 |
| Lux, MP | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Hong, J | 1 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 2 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Sirohi, B | 1 |
| Arnedos, M | 1 |
| Popat, S | 1 |
| Ashley, S | 2 |
| Nerurkar, A | 1 |
| Walsh, G | 2 |
| Johnston, S | 1 |
| Smith, IE | 4 |
| Imai, M | 1 |
| Muraki, M | 1 |
| Takamatsu, K | 1 |
| Saito, H | 1 |
| Seiki, M | 1 |
| Takahashi, Y | 1 |
| Tanabe, M | 1 |
| Ito, Y | 1 |
| Tokudome, N | 1 |
| Sugihara, T | 1 |
| Miura, H | 1 |
| Takahashi, S | 1 |
| Seto, Y | 1 |
| Iwase, T | 1 |
| Hatake, K | 1 |
| Jin, C | 1 |
| Yao, L | 1 |
| Long, J | 1 |
| Fu, DL | 1 |
| Yu, XJ | 1 |
| Xu, J | 3 |
| Yang, F | 1 |
| Ni, QX | 1 |
| Li, M | 1 |
| Zhang, J | 1 |
| Wang, D | 1 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Lu, C | 1 |
| Cheng, J | 1 |
| Cao, C | 1 |
| Pan, H | 1 |
| Dimou, A | 1 |
| Syrigos, KN | 1 |
| Sun, B | 1 |
| Yu, KR | 1 |
| Bhandari, DR | 1 |
| Jung, JW | 1 |
| Kang, SK | 1 |
| Kang, KS | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 1 |
| Zannino, D | 1 |
| van Hazel, GA | 1 |
| Robinson, B | 1 |
| Broad, A | 1 |
| Ganju, V | 1 |
| Ackland, SP | 1 |
| Forgeson, G | 1 |
| Cunningham, D | 1 |
| Saunders, MP | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Zalcberg, JR | 1 |
| Simes, RJ | 1 |
| Segawa, Y | 1 |
| Kiura, K | 1 |
| Takigawa, N | 1 |
| Kamei, H | 1 |
| Harita, S | 1 |
| Hiraki, S | 1 |
| Watanabe, Y | 1 |
| Sugimoto, K | 1 |
| Shibayama, T | 1 |
| Yonei, T | 1 |
| Ueoka, H | 1 |
| Takemoto, M | 1 |
| Kanazawa, S | 1 |
| Takata, I | 1 |
| Nogami, N | 1 |
| Hotta, K | 1 |
| Hiraki, A | 1 |
| Tabata, M | 1 |
| Matsuo, K | 1 |
| Tanimoto, M | 1 |
| Güntner, M | 1 |
| Pauligk, C | 1 |
| Scholz, M | 1 |
| Chen, R | 1 |
| Beiss, B | 1 |
| Stopatschinskaja, S | 1 |
| Lerbs, W | 1 |
| Harbeck, N | 1 |
| Jäger, E | 1 |
| Berge, EO | 1 |
| Knappskog, S | 1 |
| Lillehaug, JR | 1 |
| Lønning, PE | 1 |
| Vrdoljak, E | 1 |
| Boban, M | 1 |
| Omrcen, T | 1 |
| Hrepic, D | 1 |
| Fridl-Vidas, V | 1 |
| Boskovic, L | 1 |
| Bagliani, A | 1 |
| Baggiani, A | 1 |
| Ierardi, AM | 1 |
| Caspani, B | 1 |
| Motta, F | 1 |
| Toniolo, D | 1 |
| Belloni, P | 1 |
| Setola, E | 1 |
| Campagnoli, E | 1 |
| Tempini, S | 1 |
| Crocchiolo, R | 1 |
| Bregni, M | 1 |
| Belli, L | 1 |
| Akhlaghpoor, S | 1 |
| Aziz-Ahari, A | 1 |
| Amoui, M | 1 |
| Tolooee, S | 1 |
| Poorbeigi, H | 1 |
| Sheybani, S | 1 |
| Gunderson, LL | 1 |
| Winter, KA | 1 |
| Ajani, JA | 1 |
| Pedersen, JE | 1 |
| Moughan, J | 1 |
| Benson, AB | 1 |
| Thomas, CR | 1 |
| Mayer, RJ | 1 |
| Haddock, MG | 1 |
| Rich, TA | 1 |
| Willett, CG | 1 |
| Kimata, M | 2 |
| Otani, Y | 3 |
| Kubota, T | 4 |
| Igarashi, N | 3 |
| Yokoyama, T | 1 |
| Wada, N | 1 |
| Yoshimizu, N | 1 |
| Fujii, M | 1 |
| Kameyama, K | 1 |
| Okada, Y | 1 |
| Kumai, K | 2 |
| Kitajima, M | 4 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Shamash, J | 2 |
| Steele, JP | 1 |
| Wilson, P | 2 |
| Nystrom, M | 1 |
| Ansell, W | 2 |
| Oliver, RT | 1 |
| Grundmann, JU | 1 |
| Weisshaar, E | 1 |
| Franke, I | 1 |
| Bonnekoh, B | 1 |
| Gollnick, H | 1 |
| Konovalova, NP | 1 |
| KOOP, CE | 1 |
| FUJIMORI, M | 1 |
| SAKAUCHI, G | 1 |
| IZUO, M | 1 |
| ABE, C | 1 |
| MORITA, S | 1 |
| NASHIMOTO, T | 1 |
| ISHIKAWA, S | 1 |
| SADMITSU, H | 1 |
| KAWAI, T | 1 |
| IMANAGA, H | 1 |
| ITO, I | 1 |
| HATTORI, T | 1 |
| KOYAMA, Y | 2 |
| OBOSHI, S | 1 |
| FUJITA, H | 1 |
| KANAGAMI, H | 1 |
| NIITANI, K | 1 |
| KATSURA, T | 1 |
| HANDLER, AH | 1 |
| SARRIS, TG | 1 |
| WILLS, C | 1 |
| KONDO, T | 1 |
| UENO, K | 1 |
| KOIZUMI, A | 2 |
| YOSHIDA, K | 1 |
| TAKAHASHI, T | 4 |
| YAMAGUCHI, I | 1 |
| MAJIMA, S | 1 |
| HIRONO, I | 1 |
| KOJIMA, K | 1 |
| KACHI, H | 1 |
| OHASHI, A | 1 |
| SASAOKA, I | 1 |
| Yang, JK | 1 |
| Zhen, J | 1 |
| Shen, KP | 1 |
| Gyldenkerne, N | 1 |
| Glimelius, B | 1 |
| Frödin, JE | 1 |
| Kjaer, M | 1 |
| Pfeiffer, P | 2 |
| Hansen, F | 1 |
| Keldsen, N | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 1 |
| Sigounas, G | 1 |
| Sallah, S | 1 |
| Sigounas, VY | 1 |
| Keller, AM | 1 |
| Mennel, RG | 1 |
| Georgoulias, VA | 1 |
| Nabholtz, JM | 2 |
| Erazo, A | 1 |
| Lluch, A | 1 |
| Vogel, CL | 1 |
| Kaufmann, M | 1 |
| von Minckwitz, G | 1 |
| Henderson, IC | 1 |
| Mellars, L | 1 |
| Alland, L | 1 |
| Tendler, C | 1 |
| Urruticoechea, A | 1 |
| Archer, CD | 1 |
| Assersohn, LA | 1 |
| Gregory, RK | 2 |
| Verrill, M | 1 |
| Mendes, R | 1 |
| Johnston, SR | 1 |
| Gibson, MK | 1 |
| Holcroft, CA | 1 |
| Kvols, LK | 1 |
| Haller, D | 1 |
| Budach, V | 1 |
| Stuschke, M | 1 |
| Budach, W | 1 |
| Baumann, M | 1 |
| Geismar, D | 1 |
| Grabenbauer, G | 1 |
| Lammert, I | 1 |
| Jahnke, K | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Wust, P | 1 |
| Hinkelbein, W | 1 |
| Wernecke, KD | 1 |
| Powles, T | 1 |
| Oliver, T | 1 |
| Pelz, JO | 1 |
| Doerfer, J | 1 |
| Hohenberger, W | 1 |
| Meyer, T | 1 |
| Polyzos, A | 1 |
| Koulentianos, E | 1 |
| Tzianoumis, L | 1 |
| Sfikakis, P | 1 |
| Alexopoulos, A | 1 |
| Rigatos, G | 1 |
| Stavrinidis, E | 1 |
| Stavrakakis, J | 1 |
| Scartsilas, C | 1 |
| Papacharalambous, A | 1 |
| Alliot, C | 1 |
| Cok, G | 1 |
| Göksel, T | 1 |
| Soyer, S | 1 |
| Atil, H | 1 |
| Güzelant, A | 1 |
| Aysan, T | 1 |
| Massacesi, C | 1 |
| La Cesa, A | 1 |
| Marcucci, F | 1 |
| Pilone, A | 1 |
| Rocchi, MB | 1 |
| Zepponi, L | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Burattini, L | 1 |
| Jurczok, A | 1 |
| Schneider, A | 1 |
| Fornara, P | 1 |
| Rahman-Roblick, R | 1 |
| Roblick, UJ | 1 |
| Hellman, U | 1 |
| Conrotto, P | 1 |
| Liu, T | 1 |
| Becker, S | 1 |
| Hirschberg, D | 1 |
| Jörnvall, H | 1 |
| Auer, G | 1 |
| Wiman, KG | 1 |
| Liedberg, F | 1 |
| Vormittag, L | 1 |
| Kornek, GV | 2 |
| Gruhsmann, B | 1 |
| Lenauer, A | 1 |
| Föger, A | 1 |
| Depisch, D | 3 |
| Lang, F | 2 |
| Scheithauer, W | 3 |
| Park, BB | 1 |
| Im, YH | 1 |
| Hwang, IG | 1 |
| Lee, SC | 1 |
| Ahn, JS | 1 |
| Ahn, MJ | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Mrozek, E | 1 |
| Kolesar, J | 1 |
| Young, D | 1 |
| Allen, J | 1 |
| Villalona-Calero, M | 1 |
| Shapiro, CL | 1 |
| Chalasani, P | 1 |
| Kurtin, S | 1 |
| Dragovich, T | 1 |
| Patt, YZ | 1 |
| Chuang, VP | 1 |
| Wallace, S | 1 |
| Benjamin, RS | 1 |
| Fuqua, R | 1 |
| Mavligit, GM | 1 |
| Tanigawa, N | 1 |
| Mizuno, Y | 1 |
| Hashimura, T | 1 |
| Honda, K | 1 |
| Satomura, K | 1 |
| Hikasa, Y | 1 |
| Niwa, O | 1 |
| Sugahara, T | 1 |
| Yoshida, O | 1 |
| Kern, DH | 1 |
| Kelsen, D | 1 |
| Perez, DJ | 1 |
| Powles, TJ | 4 |
| Gazet, JC | 2 |
| Ford, HT | 2 |
| Coombes, RC | 3 |
| Budd, GT | 1 |
| Groppe, CW | 1 |
| Itoh, J | 1 |
| Nakagawa, H | 1 |
| Sasaki, H | 1 |
| Katoh, T | 1 |
| Sternberg, CN | 1 |
| Magill, GB | 1 |
| Sordillo, PP | 1 |
| Cheng, EW | 1 |
| Franklin, R | 1 |
| Steiger, Z | 2 |
| Vaishampayan, G | 1 |
| Asfaw, I | 2 |
| Rosenberg, J | 1 |
| Loh, J | 1 |
| Hoschner, J | 1 |
| Miller, P | 1 |
| Tannock, IF | 1 |
| Alcobendas, F | 1 |
| Milla, A | 1 |
| Estape, J | 1 |
| Curto, J | 1 |
| Pera, C | 1 |
| Perry, DJ | 1 |
| Tanaka, T | 1 |
| Iguchi, K | 1 |
| Hashimoto, I | 1 |
| Nomura, Y | 2 |
| Kanda, K | 1 |
| Tashiro, H | 1 |
| Hamada, Y | 1 |
| Saeki, K | 1 |
| Burk, K | 2 |
| Gropp, C | 2 |
| Rodeck, G | 1 |
| Harris, MA | 1 |
| Byrne, PJ | 1 |
| Smith, FP | 1 |
| Ueno, W | 1 |
| Schlesinger, C | 1 |
| Oishi, S | 1 |
| Schein, PS | 1 |
| Ozaki, A | 1 |
| Saijo, N | 1 |
| Beppu, Y | 1 |
| Takahashi, K | 1 |
| Shimizu, E | 1 |
| Hoshi, A | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Murphy, J | 1 |
| Beck, TM | 2 |
| Curtis, PW | 1 |
| Woodard, DA | 2 |
| Hart, NE | 2 |
| Smith, CE | 2 |
| Orita, K | 2 |
| Miwa, H | 1 |
| Yamashita, H | 1 |
| Kurimoto, M | 1 |
| Murasawa, K | 1 |
| Tseng, MH | 1 |
| Luch, J | 1 |
| Mittelman, A | 1 |
| Dennis, JW | 1 |
| Laferté, S | 1 |
| Man, MS | 1 |
| Elliott, BE | 1 |
| Kerbel, RS | 1 |
| Chahinian, AP | 1 |
| Green, G | 1 |
| Holland, JF | 1 |
| Ridolfi, R | 2 |
| Casadei Giunchi, D | 1 |
| Cortesi, C | 1 |
| Maltoni, M | 1 |
| Ravaioli, A | 2 |
| Amadori, D | 2 |
| Kasimis, BS | 2 |
| Moran, EM | 2 |
| Miller, JB | 2 |
| Forbes, KA | 2 |
| Kaneshiro, CA | 2 |
| Poblet, MT | 1 |
| Williams, JL | 1 |
| Konits, PH | 1 |
| Aisner, J | 1 |
| van Echo, DA | 1 |
| Lichtenfeld, K | 1 |
| Wiernik, PH | 1 |
| Conroy, JF | 1 |
| Roda, PI | 1 |
| Brodsky, I | 1 |
| Kahn, SB | 1 |
| Bulova, SI | 1 |
| Pequignot, E | 1 |
| van Oosterom, AT | 1 |
| Hamersma, E | 1 |
| Engelsman, E | 1 |
| Kinami, Y | 1 |
| Konishi, K | 1 |
| Shinmura, K | 1 |
| Takada, M | 1 |
| Sakuma, H | 1 |
| Nagakawa, T | 1 |
| Miyazaki, I | 2 |
| Fujimoto, S | 2 |
| Miyazaki, M | 1 |
| Okui, K | 1 |
| Oster, MW | 1 |
| Park, Y | 1 |
| Sengeløv, L | 1 |
| Nielsen, OS | 1 |
| Kamby, C | 1 |
| von der Maase, H | 1 |
| Pacini, P | 2 |
| Tucci, E | 2 |
| Algeri, R | 2 |
| Rinaldini, M | 2 |
| Guarnieri, A | 1 |
| Valzelli, S | 1 |
| Neri, B | 2 |
| Gebbia, V | 2 |
| Testa, A | 1 |
| Valenza, R | 1 |
| Latteri, M | 1 |
| Bajardi, G | 1 |
| Mastrandrea, G | 1 |
| Cipolla, C | 1 |
| Pischedda, G | 1 |
| Curto, G | 1 |
| Cannata, G | 1 |
| Vandenbroucke, F | 1 |
| Van Poppel, H | 2 |
| Derluyn, J | 2 |
| Popelier, G | 2 |
| Casselman, J | 2 |
| Billiet, I | 2 |
| Vanuytsel, L | 1 |
| Paridaens, R | 2 |
| Baert, L | 2 |
| Nio, Y | 1 |
| Tamura, K | 1 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Hayashi, H | 1 |
| Ishigami, S | 1 |
| Araya, S | 1 |
| Imamura, M | 1 |
| Izumi, R | 1 |
| Shimizu, K | 1 |
| Iyobe, T | 1 |
| Ii, T | 1 |
| Yagi, M | 1 |
| Matsui, O | 1 |
| Nonomura, A | 1 |
| Perrone, F | 2 |
| De Placido, S | 2 |
| Carlomagno, C | 2 |
| Gravina, A | 1 |
| De Laurentiis, M | 2 |
| Del Mastro, L | 1 |
| Gridelli, C | 2 |
| Pagliarulo, C | 2 |
| Bianco, AR | 2 |
| Taguchi, T | 2 |
| Tanikawa, K | 2 |
| Sano, K | 1 |
| Nakamura, H | 2 |
| Okawa, T | 2 |
| Miura, T | 1 |
| Ogawa, N | 3 |
| Kondo, M | 1 |
| Nuzzo, F | 1 |
| Ruggiero, A | 1 |
| Furukawa, T | 1 |
| Watanabe, M | 3 |
| Hoffman, RM | 1 |
| Allal, A | 1 |
| Kurtz, JM | 1 |
| Pipard, G | 1 |
| Marti, MC | 1 |
| Miralbell, R | 1 |
| Popowski, Y | 1 |
| Egeli, R | 1 |
| Satou, T | 1 |
| Kornek, G | 1 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Schenk, T | 1 |
| Pirker, R | 1 |
| Falkson, CI | 2 |
| Falkson, G | 2 |
| Falkson, CB | 2 |
| Falkson, HC | 2 |
| Brockmann, WP | 1 |
| Wiegel, T | 1 |
| Sommer, K | 1 |
| Steiner, P | 1 |
| Hübener, KH | 1 |
| Dennis, IF | 1 |
| Ramsay, JR | 1 |
| Workman, P | 1 |
| Bleehen, NM | 1 |
| Saiki, I | 1 |
| Yoneda, J | 1 |
| Kobayashi, H | 1 |
| Igarashi, Y | 1 |
| Komazawa, H | 1 |
| Ishizaki, Y | 1 |
| Kato, I | 1 |
| Azuma, I | 1 |
| van den Broucke, F | 1 |
| van Uytsel, L | 1 |
| Ozaki, H | 1 |
| Kinoshita, T | 1 |
| Kosuge, T | 1 |
| Yamamoto, J | 1 |
| Shimada, K | 1 |
| Inoue, K | 2 |
| Mukai, K | 1 |
| Muhonen, T | 1 |
| Jantunen, I | 1 |
| Pertovaara, H | 1 |
| Voutilainen, L | 1 |
| Maiche, A | 1 |
| Blomqvist, C | 1 |
| Pyrhönen, S | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Morimoto, T | 1 |
| Ogawa, M | 2 |
| Sugimachi, K | 1 |
| Toge, T | 1 |
| Dohi, K | 1 |
| Monden, Y | 1 |
| Zoetmulder, FA | 1 |
| Sugarbaker, PH | 1 |
| Takahashi, M | 1 |
| Mutou, T | 1 |
| Kobayashi, K | 1 |
| Toyosawa, T | 1 |
| Isawa, E | 1 |
| Sumida, M | 1 |
| Ohkubo, H | 1 |
| Chan, AK | 1 |
| Wong, AO | 1 |
| Langevin, JM | 1 |
| Jenken, DA | 1 |
| Khoo, R | 1 |
| Heine, JA | 1 |
| Buie, WD | 1 |
| Johnson, DR | 1 |
| Hao, W | 1 |
| Messbarger, L | 1 |
| Joshi, SS | 1 |
| Otto, T | 1 |
| Krege, S | 1 |
| Otto, B | 1 |
| Goepel, M | 1 |
| Rübben, H | 1 |
| Kusenda, Z | 1 |
| Kerger, J | 1 |
| Awada, A | 1 |
| Geurs, F | 1 |
| Van Vreckem, A | 1 |
| Habboubi, N | 1 |
| Piccart, MJ | 1 |
| Chang, JC | 1 |
| Blaszkowsky, L | 1 |
| Crown, J | 2 |
| Patiutko, IuI | 1 |
| Kotel'nikov, AG | 1 |
| Badalian, KhV | 1 |
| Sagaĭdak, IV | 1 |
| Ducreux, M | 1 |
| Gil-Delgado, M | 1 |
| André, T | 1 |
| Ychou, M | 1 |
| de Gramond, A | 1 |
| Khayat, D | 1 |
| Matsuzaki, SW | 1 |
| Teramoto, T | 1 |
| Tamaki, K | 1 |
| Tanzawa, K | 1 |
| Hong, RL | 1 |
| Sheen, TS | 1 |
| Ko, JY | 1 |
| Hsu, MM | 1 |
| Wang, CC | 1 |
| Ting, LL | 1 |
| Tanner, J | 1 |
| Dunst, J | 2 |
| Quietzsch, D | 1 |
| Daikeler, T | 1 |
| Kollmannsberger, C | 1 |
| Mayer, F | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Juvekar, AS | 1 |
| Amonkar, AJ | 1 |
| D'cruz, AK | 1 |
| Saikaia, T | 1 |
| Pradhan, S | 1 |
| Guarneri, A | 1 |
| Barsanti, G | 1 |
| Bastiani, P | 1 |
| Marzano, S | 1 |
| Fallai, C | 1 |
| Kretzschmar, A | 1 |
| Reichardt, P | 1 |
| Thuss-Patience, PC | 1 |
| Hohenberger, P | 1 |
| Benter, T | 1 |
| Dörken, B | 1 |
| Köhne, CH | 1 |
| Focan, C | 1 |
| Bury, J | 1 |
| Beauduin, M | 1 |
| Herman, ML | 1 |
| Vindevoghel, A | 1 |
| Brohée, D | 1 |
| Lecomte, M | 1 |
| Grumett, SA | 1 |
| Archer, VR | 1 |
| Midgley, R | 1 |
| Mulholland, P | 1 |
| Nicum, S | 1 |
| Blewitt, L | 1 |
| Kerr, DJ | 1 |
| Gray, R | 1 |
| McConkey, C | 1 |
| Sutcliffe, R | 1 |
| Quilliam, J | 1 |
| Makinde, V | 1 |
| Lowndes, S | 1 |
| Li, N | 1 |
| van Agthoven, M | 1 |
| Willemse, P | 1 |
| Uyl-de Groot, C | 1 |
| Kato, Y | 2 |
| Onishi, H | 2 |
| Machida, Y | 2 |
| Rixe, O | 1 |
| Tan, SM | 1 |
| Cheung, KL | 1 |
| Willsher, PC | 1 |
| Blamey, RW | 1 |
| Chan, SY | 1 |
| Robertson, JF | 1 |
| Haensgen, G | 1 |
| Seitz, JF | 1 |
| Duffaud, F | 1 |
| Dahan, L | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Manziuk, LV | 1 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Brugger, S | 1 |
| Ullrich-Pur, H | 1 |
| Valencak, J | 1 |
| Raderer, M | 1 |
| Fiebiger, W | 1 |
| Kovats, E | 1 |
| Stockler, M | 1 |
| Raghavan, D | 1 |
| McCaughan, BC | 1 |
| Grygiel, J | 1 |
| McNeil, E | 1 |
| Gianoutsos, P | 1 |
| Degardin, M | 1 |
| Hecquet, B | 1 |
| Bonneterre, J | 1 |
| Adenis, A | 1 |
| Pion, JM | 1 |
| Demaille, A | 1 |
| Oguro, Y | 1 |
| Mizutani, J | 1 |
| Hiraoka, T | 1 |
| Yamashita, R | 1 |
| Miyauchi, Y | 1 |
| Cold, S | 1 |
| Rose, C | 1 |
| Arika, T | 1 |
| Amemiya, K | 1 |
| Nomoto, K | 1 |
| Cunliffe, WJ | 1 |
| Douglass, HO | 2 |
| Araújo, CM | 1 |
| Souhami, L | 1 |
| Gil, RA | 1 |
| Carvalho, R | 1 |
| Garcia, JA | 1 |
| Froimtchuk, MJ | 1 |
| Pinto, LH | 1 |
| Canary, PC | 1 |
| Rausa, L | 1 |
| Russo, A | 1 |
| Gebbia, N | 1 |
| D'Alessandro, N | 1 |
| Palmeri, S | 1 |
| Mitomi, T | 1 |
| Tsuchiya, S | 2 |
| Iijima, N | 1 |
| Aso, K | 1 |
| Suzuki, K | 1 |
| Nishiyama, K | 1 |
| Amano, T | 1 |
| Murayama, N | 1 |
| Oka, H | 1 |
| Yanagawa, M | 1 |
| Suzuki, S | 1 |
| Kameda, K | 1 |
| Nakano, S | 1 |
| Kinbara, H | 1 |
| Araki, T | 1 |
| Sakurai, M | 1 |
| Hioki, T | 1 |
| Sugimura, Y | 1 |
| Tochigi, H | 1 |
| Fujii, T | 1 |
| Yokomori, T | 1 |
| Topham, C | 1 |
| Glees, J | 1 |
| Rawson, NS | 1 |
| Woods, EM | 1 |
| Feliu, J | 1 |
| Girón, CG | 1 |
| González-Baron, M | 1 |
| Berrocal, A | 1 |
| Barón-Saura, JM | 1 |
| Tomita, M | 1 |
| Ishikawa, H | 1 |
| Nakagoe, T | 1 |
| Shimizu, T | 1 |
| Hirano, T | 1 |
| Eida, K | 1 |
| Ishii, T | 1 |
| Tobinaga, K | 1 |
| Kotake, Y | 1 |
| Nogawa, T | 1 |
| O'Brien, ME | 1 |
| Bayliss, EJ | 1 |
| Stewart, ME | 1 |
| Smyth, JF | 1 |
| Rodger, A | 1 |
| Leonard, RC | 1 |
| Giannone, L | 1 |
| Brenner, DE | 1 |
| Jones, HW | 1 |
| Greco, FA | 1 |
| Burnett, LS | 1 |
| Leichman, L | 1 |
| Herskovic, A | 1 |
| Leichman, CG | 1 |
| Lattin, PB | 1 |
| Tapazoglou, E | 1 |
| Rosenberg, JC | 1 |
| Arbulu, A | 1 |
| Kinzie, J | 1 |
| Lahousen, M | 1 |
| Pickel, H | 1 |
| Tamussino, K | 1 |
| Alberts, DS | 1 |
| Kronmal, R | 1 |
| Baker, LH | 1 |
| Stock-Novack, DL | 1 |
| Surwit, EA | 1 |
| Boutselis, JG | 1 |
| Hannigan, EV | 1 |
| Aoki, Y | 1 |
| Tabuse, Y | 1 |
| Tanimura, H | 1 |
| Katsumi, M | 1 |
| Asae, M | 1 |
| Ichimiya, G | 1 |
| Imai, T | 1 |
| Ooshima, K | 1 |
| Kakihara, M | 1 |
| Kashitani, M | 1 |
| Habr-Gama, A | 1 |
| da Silva e Sousa Júnior, AH | 1 |
| Nadalin, W | 1 |
| Gansl, R | 1 |
| da Silva, JH | 1 |
| Pinotti, HW | 1 |
| Hojo, K | 1 |
| Queisser, W | 2 |
| Flechtner, H | 2 |
| Heim, ME | 2 |
| Kabelitz, K | 1 |
| Massner, B | 1 |
| Edler, L | 1 |
| Lyss, AP | 1 |
| Luedke, SL | 1 |
| Einhorn, L | 1 |
| Luedke, DW | 1 |
| Raney, M | 1 |
| Bruckner, HW | 1 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 1 |
| Menichetti, ET | 1 |
| Silva, RR | 1 |
| Tummarello, D | 1 |
| Miseria, S | 1 |
| Torresi, U | 1 |
| Cellerino, R | 1 |
| Voigt, H | 1 |
| Aigner, KR | 1 |
| Link, KH | 1 |
| Walther, H | 1 |
| Müller, H | 1 |
| Crinó, L | 2 |
| Darwish, S | 1 |
| Corgna, E | 1 |
| Meacci, ML | 1 |
| Di Costanzo, F | 2 |
| Buzzi, F | 2 |
| Fornari, G | 1 |
| Santi, F | 1 |
| Ballatori, E | 1 |
| Luccioli, L | 1 |
| Belpomme, D | 1 |
| Cour, V | 1 |
| Gisselbrecht, C | 1 |
| Le Rol, A | 1 |
| Mignot, L | 1 |
| Marty, M | 1 |
| Godeffroy, W | 1 |
| Maral, J | 1 |
| Gori, S | 1 |
| Tonato, M | 1 |
| Grignani, F | 1 |
| Davis, S | 1 |
| Kasuga, Y | 1 |
| Senga, O | 1 |
| Hanamura, N | 1 |
| Iida, F | 1 |
| Oota, H | 1 |
| Katsuyama, T | 1 |
| Eagan, RT | 1 |
| Frytak, S | 1 |
| Richardson, RL | 1 |
| Creagan, ET | 1 |
| Nichols, WC | 1 |
| Smith, G | 1 |
| Elton, RA | 1 |
| Chisholm, GD | 1 |
| Newsam, JE | 1 |
| Hargreave, TB | 1 |
| Ahmann, FR | 2 |
| Pugh, R | 1 |
| O'Connell, MJ | 1 |
| Schutt, AJ | 1 |
| Moertel, CG | 1 |
| Hahn, RG | 1 |
| Neumann, R | 1 |
| Common, H | 1 |
| Ricken, D | 1 |
| Erlichman, C | 1 |
| Rauth, AM | 1 |
| Battistella, R | 1 |
| Fine, S | 1 |
| Henss, H | 1 |
| Arnold, H | 1 |
| Fritze, D | 1 |
| Herrmann, R | 1 |
| Fritsch, H | 1 |
| Fritz, M | 1 |
| Trux, FA | 1 |
| Cruciani, G | 1 |
| Tienghi, A | 1 |
| Molinari, AL | 1 |
| Fiorentini, G | 1 |
| Rosti, G | 1 |
| Turci, D | 1 |
| Marangolo, M | 1 |
| Dees, A | 1 |
| Verweij, J | 1 |
| van Putten, WL | 1 |
| Stoter, G | 1 |
| D'Elia, JA | 1 |
| Aslani, M | 1 |
| Schermer, S | 1 |
| Cloud, L | 1 |
| Bothe, A | 1 |
| Dzik, W | 1 |
| Mohiuddin, M | 1 |
| Cantor, RJ | 1 |
| Biermann, W | 1 |
| Weiss, SM | 1 |
| Barbot, D | 1 |
| Rosato, FE | 1 |
| Hamanaka, T | 1 |
| Ohgoshi, M | 1 |
| Kawahara, K | 1 |
| Yamakawa, K | 1 |
| Tsuruo, T | 1 |
| Tsukagoshi, S | 1 |
| Keymling, M | 1 |
| Lübke, HJ | 1 |
| Wörner, W | 1 |
| Lakshmi, MS | 1 |
| Hunt, G | 1 |
| Sherbet, GV | 1 |
| Migeod, F | 1 |
| Gerlach, D | 1 |
| Kress, M | 1 |
| Hoffmann, W | 1 |
| Farroukh, R | 1 |
| Seeber, S | 1 |
| Kanno, A | 1 |
| Tanaka, S | 1 |
| Ito, T | 1 |
| Ban, K | 1 |
| Oshita, H | 1 |
| Fukata, D | 1 |
| Sakai, N | 1 |
| Kashizuka, T | 1 |
| Hatoh, T | 1 |
| Ruckdeschel, JC | 2 |
| Finkelstein, DM | 2 |
| Ettinger, DS | 2 |
| Creech, RH | 1 |
| Mason, BA | 1 |
| Joss, RA | 1 |
| Vogl, S | 1 |
| Kris, MG | 1 |
| Gralla, RJ | 1 |
| Wertheim, MS | 1 |
| Kelsen, DP | 1 |
| O'Connell, JP | 1 |
| Burke, MT | 1 |
| Fiore, JJ | 1 |
| Cibas, IR | 1 |
| Heelan, RT | 1 |
| Miller, TP | 1 |
| Vance, RB | 1 |
| Rodney, SR | 1 |
| Faedi, M | 1 |
| Amadori, M | 1 |
| Gentilini, P | 1 |
| Biserni, R | 1 |
| Bonaguri, C | 1 |
| Metter, GE | 1 |
| Oda, M | 1 |
| Koga, S | 1 |
| Maeta, M | 1 |
| Villani, F | 1 |
| Comazzi, R | 1 |
| Lacaita, G | 1 |
| Guindani, A | 1 |
| Genitoni, V | 1 |
| Volonterio, A | 1 |
| Brambilla, MC | 1 |
| Bocian, RC | 1 |
| Dray, S | 1 |
| Ben-Efraim, S | 1 |
| Mokyr, MB | 1 |
| de Riese, W | 1 |
| Löbenau, S | 1 |
| Radford, JA | 1 |
| Knight, RK | 1 |
| Rubens, RD | 1 |
| Ikeda, K | 1 |
| Inagaki, J | 1 |
| Horikoshi, N | 1 |
| Usui, N | 1 |
| Nakada, H | 1 |
| Adachi, K | 1 |
| Yamazaki, H | 1 |
| Tada, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063] | Phase 2 | 9 participants (Actual) | Interventional | 2013-04-25 | Completed | ||
| Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study[NCT04153734] | Phase 2 | 21 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| A Prospective Phase Ⅱ Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer[NCT02573506] | Phase 2 | 99 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Split-course Thoracic Radiotherapy Combined With Nab-paclitaxel Plus Nedaplatin for Local Advanced NSCLC With Impaired Baseline Pulmonary Function[NCT04212052] | Phase 2 | 71 participants (Anticipated) | Interventional | 2019-12-01 | Active, not recruiting | ||
| A Phase II,Randomized Controlled Clinical Trial of Staged Thoracic Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin Twice a Week for Locally Advanced NSCLC[NCT04524299] | Phase 2 | 160 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| Hypofractionated Radiotherapy Followed by Hypofractionated Boost With Weekly Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: A Prospective, Single Arm Phase II Study[NCT03900117] | Phase 2 | 77 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal[NCT00003596] | Phase 3 | 682 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (Paclitaxel, Carboplatin) | 3 |
| Arm 2 (Veliparib, Paclitaxel, Carboplatin) | 3 |
15 reviews available for mitomycin and Metastase
| Article | Year |
|---|---|
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review.
Topics: Adult; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction S | 2022 |
Is there a role for mitomycin C in metastatic colorectal cancer?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neopla | 2010 |
Chemotherapy of esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub | 1984 |
[Mechanism of neoplasm metastasis and treatment strategy].
Topics: Humans; Immunotoxins; Mitomycin; Neoplasm Invasiveness; Neoplasm Metastasis; Peritoneal Neoplasms; S | 1995 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
[Ways of improving long-term results of treatment in resectable pancreatic cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Evaluation | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1999 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1992 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1992 |
The rationale for early postoperative intraperitoneal chemotherapy for gastric cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Evaluation; Fluorouracil; Humans; Infusions, Pa | 1991 |
Rationale for the intraperitoneal approach to surgical adjuvant chemotherapy of gastric cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parent | 1991 |
Hemolytic-uremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1987 |
[A case of an exogastric developing-type carcinoma of the stomach and a review of thirty nine cases reported in Japan].
Topics: Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy P | 1988 |
74 trials available for mitomycin and Metastase
| Article | Year |
|---|---|
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; D | 2014 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2015 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine | 2009 |
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2010 |
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2011 |
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2012 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
IPM chemotherapy in cytokine refractory renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Ci | 2003 |
[Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drugs, Chinese Herbal; Female; F | 2003 |
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compound | 2004 |
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Sur | 2005 |
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2006 |
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Top | 2008 |
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo | 1984 |
Mitomycin C as an adjuvant in resected gastric cancer.
Topics: Actuarial Analysis; Adult; Aged; Clinical Trials as Topic; Female; Follow-Up Studies; Gastrectomy; H | 1983 |
Treatment of advanced breast cancer with two doxorubicin-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1984 |
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mitomycin; Mitomycins; N | 1980 |
Systemic mitomycin C as second-line treatment for metastatic urothelial cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisp | 1995 |
Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administ | 1994 |
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epir | 1994 |
Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Humans; Male; Middle Aged; Mitomycin; Neoplasm Meta | 1995 |
Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1994 |
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1994 |
[Multi-center cooperative phase II study of combined infusion of PJ-203 (degradable starch microspheres) into hepatic artery in metastatic liver cancer].
Topics: Adult; Aged; Embolization, Therapeutic; Female; Follow-Up Studies; Hepatic Artery; Humans; Injection | 1993 |
[Comparative clinical study in metastatic liver cancer between intra-arterial infusion of mitomycin C alone and intra-arterial infusion of mitomycin C combined with PJ-203 (degradable starch microspheres)].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow | 1993 |
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1993 |
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1993 |
A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Medro | 1993 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.
Topics: Benzaldehydes; Drug Combinations; Drug Evaluation; Gastrointestinal Neoplasms; Half-Life; Humans; Me | 1993 |
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 1993 |
Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial.
Topics: Aged; Combined Modality Therapy; Follow-Up Studies; Humans; Male; Mitomycin; Neoplasm Metastasis; Or | 1993 |
Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Filgrastim; G | 1996 |
Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Can
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 1996 |
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance, | 1997 |
Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Topics: Adult; Aged; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplas | 1997 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 1997 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1998 |
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin | 1999 |
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disea | 1999 |
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps | 1999 |
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2000 |
Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Human | 2000 |
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2000 |
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2001 |
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
[A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1992 |
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1992 |
A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1991 |
Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemothera | 1992 |
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Fol | 1991 |
Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1987 |
[Clinical effect of combined chemotherapy with UFT, MMC and OK-432 in recurring or advanced cancer of the digestive organs].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neo | 1989 |
Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluat | 1989 |
Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Eto | 1988 |
Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1987 |
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To | 1988 |
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophos | 1986 |
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic; Fema | 1986 |
Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Trials as Topic | 1986 |
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1985 |
Gastric cancer: overview of current therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
132 other studies available for mitomycin and Metastase
| Article | Year |
|---|---|
Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedur | 2020 |
MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Cisplatin; Colorectal Neo | 2021 |
[Regional chemotherapy in treatment of patients with unresectable liver metastases of uveal melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoembolization, Therape | 2016 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2013 |
[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2014 |
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2014 |
Metabolic alteration--Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug | 2015 |
Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclin- | 2015 |
Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cape | 2016 |
Platinum-based chemotherapy in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 2008 |
Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gr | 2008 |
Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal | 2009 |
Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation.
Topics: Adult; Animals; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Division; Extrace | 2010 |
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemot | 2010 |
Alterations of the retinoblastoma gene in metastatic breast cancer.
Topics: Adult; Anthracyclines; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulati | 2011 |
Hypoxic liver perfusion with mitomycin-C for treating multifocal metastases and unresectable primary tumours: a single-centre series of 42 patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Cell Hypoxia; Disease-Free Survival; Feasibility Studies; | 2011 |
Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoemboliz | 2012 |
Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Cell Survival; Coloring Ag | 2002 |
Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome.
Topics: Adult; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Fatal Outcome; Fluorouracil; Hum | 2003 |
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Resp | 2003 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
STUDIES ON REGIONAL PERFUSION AND INTRA-ARTERIAL INFUSION FOR CANCER CHEMOTHERAPY.
Topics: Antineoplastic Agents; Breast Neoplasms; Celiac Artery; Chemotherapy, Cancer, Regional Perfusion; Co | 1964 |
[PREVENTION OF THE RECURRENCE OF CANCER].
Topics: Animals; Biomedical Research; Genetic Diseases, X-Linked; Hormones; Leukemia, Hairy Cell; Lymphatic | 1964 |
[CHEMOTHERAPY OF PRIMARY AND METASTATIC HEPATIC CANCER BY HEPATIC ARTERY INFUSION].
Topics: Blood; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Function Tests; Liver Neoplasms; Mi | 1964 |
[METASTATIC LUNG TUMOR: CHARACTERISTICS OF THE X-RAY PICTURE AND THE TREATMENT OF CHOICE IN PRIMARY TUMORS].
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Neoplasms; Pneumonect | 1964 |
CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE.
Topics: Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Melphalan; Mice; Mitomycin; Mitom | 1964 |
THE ADVERSE EFFECTS OF CANCER CHEMOTHERAPY.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma, Ehrlich Tumor; Cortisone; Cyclophosphamide; D | 1964 |
[EXPERIMENTAL STUDIES ON THE PREVENTION OF HEMATOGENIC METASTASIS OF CANCER WITH ANTICANCER DRUGS].
Topics: Ascites; Blood Circulation; Injections, Intravenous; Liver Neoplasms; Mitomycin; Mitomycins; Neoplas | 1964 |
INHIBITORY EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS ON LIVER METASTASIS OF INTRAPORTALLY INOCULATED MOUSE ASCITES HEPATOMA.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Injection | 1964 |
[EXPERIMENTAL STUDIES ON THE EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS TO LIVER METASTASIS FOLLOWING PORTAL INJECTION OF MOUSE ASCITES HEPATOMA].
Topics: Animals; Ascites; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Mice; Mitomycin; Mitom | 1963 |
[DEVELOPMENT OF FREE-CELL SUBLINES OF THE ASCITES HEPATOMA AH-130 AND THEIR BIOLOGICAL PROPERTIES].
Topics: Ascites; Carcinoma, Hepatocellular; Chromosomes; Electrons; Liver Neoplasms; Mechlorethamine; Micros | 1964 |
Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; C | 2004 |
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Cyto | 2005 |
A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.
Topics: Animals; Body Weight; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; | 2005 |
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; H | 1989 |
Second and third line chemotherapy in advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1989 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2006 |
[Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide | 2006 |
Inhibition of tumor implantation after laparoscopy by specific oligopeptides: a novel approach to adjuvant intraperitoneal therapy to prevent tumor implantation in an animal model.
Topics: Analysis of Variance; Animals; Chi-Square Distribution; Female; Injections, Intraperitoneal; Laparos | 2007 |
p53 targets identified by protein expression profiling.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Electrophoresis, Gel, Two-Dimensional; Gene Expressi | 2007 |
The present article describes decreased intraperitoneal urothelial tumor cell growth by administration of antiadhesive oligopeptides or mitomycin.
Topics: Animals; Female; Injections, Intraperitoneal; Laparoscopy; Mice; Mice, Inbred C57BL; Mitomycin; Mode | 2007 |
UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2007 |
Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Female; Genes, BRCA | 2008 |
Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1983 |
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi | 1984 |
Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1984 |
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Doxorubicin; Drug | 1983 |
[Comparison between continuous arterial infusion chemotherapy and mitomycin C microcapsule administration in primary and metastatic liver cancer].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Capsules; Carcinoma, Hepatocellular; Hepatic Artery; | 1983 |
Combined modality therapy for esophageal squamous cell carcinoma.
Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso | 1983 |
Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Evaluation; Drug Therapy, Combination; Hum | 1983 |
Reversible microangiopathic hemolytic anemia after mitomycin C.
Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Antibiotics, Antineoplastic; Humans; Male; Mitomycin; Mitom | 1983 |
[Chemotherapy of gastric cancer patients with hepatic metastases].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Fluorouracil; Humans; Liver Neoplasms; Mitomycin; | 1983 |
[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Thera | 1983 |
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1983 |
[Analysis of the mechanism of cancer metastasis by using anticancer agents].
Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Killer Cells, Natural; Liver Neoplasms; Ma | 1984 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1984 |
[Antitumor effect of new lymphokine OH-1 on BDF1 mice bearing Lewis lung carcinoma].
Topics: Animals; Cyclophosphamide; Doxorubicin; Female; Lung Neoplasms; Lymphokines; Mice; Mitomycin; Mitomy | 1984 |
[The injurious effect of granulocytes and mitomycin C added to cultured human vascular endothelium].
Topics: Antibiotics, Antineoplastic; Blood Vessels; Cell Adhesion; Cells, Cultured; Endopeptidases; Endothel | 1983 |
Regional intra-arterial mitomycin C infusion in previously treated patients with metastatic colorectal cancer and concomitant measurement of serum drug level.
Topics: Adenocarcinoma; Aged; Bone Marrow; Colonic Neoplasms; Female; Humans; Infusions, Intra-Arterial; Mal | 1984 |
Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
Topics: Animals; Antibiotics, Antineoplastic; Immunization, Passive; Immunotherapy; Mice; Mice, Inbred DBA; | 1984 |
A retrospective study of FAM regimen in 38 patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Midd | 1984 |
Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Male; Middl | 1983 |
Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Middle Aged; Mitomycin; Mi | 1981 |
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; | 1981 |
[Effect of cancer chemotherapy for unresectable cancer of the pancreas].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Mal | 1982 |
[Antitumor treatment for synchronous hepatic metastasis from stomach cancer].
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver N | 1982 |
Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1983 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl | 1993 |
Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Fol | 1993 |
[Importance of systemic administration of pyrimidine after thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gas | 1993 |
Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs.
Topics: Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Dose-Re | 1993 |
An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Combined Modality Therapy; Duod | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
Topics: Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mito | 1997 |
"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 1997 |
Immunosuppression by metastatic lymphoma derived altered retroviral gp70 molecule.
Topics: Abelson murine leukemia virus; Animals; Cell Line; Cell Transformation, Neoplastic; Gene Products, e | 1997 |
[Therapeutic effect of matrix metalloproteinase inhibitor (R-94138) for peritoneal metastasis of stomach neoplasm models].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Injectio | 1997 |
Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice.
Topics: Acetamides; Animals; Antineoplastic Agents; Cisplatin; Gelatinases; Humans; Male; Matrix Metalloprot | 1999 |
Chemosensitivity of advanced larynx carcinoma cells in vitro and significance of multidrug resistance markers in these tumors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; C | 1998 |
The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2001 |
A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2001 |
Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis.
Topics: Animals; Area Under Curve; Chitin; Chitosan; Drug Carriers; Injections, Intravenous; Lactose; Liver | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
Efficacy of lactosaminated and intact N-succinylchitosan-mitomycin C conjugates against M5076 liver metastatic cancer.
Topics: Amino Sugars; Animals; Area Under Curve; Chitin; Chitosan; Drug Administration Schedule; Fluorescein | 2002 |
Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1992 |
[Trend and problems of chemotherapy of stomach neoplasms with metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Mitomycin; Neoplasm | 1992 |
Promotion of hepatic metastases by liver resection in the rat.
Topics: Animals; Fluorouracil; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Mi | 1992 |
Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice.
Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Immunotherapy; Lung Neoplasms; Male; M | 1992 |
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Melph | 1991 |
[A clinical study on renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lymphatic Metastasis; Mal | 1991 |
[A clinical study of vitamin A concerning auxiliary chemotherapies after operation of gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrectomy; Humans; Lymphatic | 1991 |
Alternating chemotherapy in advanced gastric cancer. A phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Doxoru | 1991 |
[The usefulness of UFT administration in colorectal cancer with emphasis on postoperative administration (Part 3)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1991 |
A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluo | 1990 |
Combination chemotherapy for patients with advanced carcinoma of the cervix: trial of mitomycin-C, vincristine, bleomycin, and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Follow-Up | 1987 |
Nonoperative therapy for squamous-cell cancer of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1987 |
Chemotherapy for advanced and/or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1987 |
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1989 |
[Surgery for far-advanced colorectal cancer--extension of surgical indication and its results].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Neoplasm Metastasis; | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
Etoposide and mitomycin-C in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Etopo | 1989 |
[Systemically administered regional tumor therapy. Regional hemi-body chemotherapy of metastatic malignant melanoma--an experimental therapy concept].
Topics: Adult; Antineoplastic Agents; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Cispl | 1989 |
[Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1987 |
Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leuko | 1986 |
[A case of bilateral metastatic breast carcinoma from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Lomust | 1986 |
An aggressive, sequential combination chemotherapy regimen in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 1986 |
Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Ethoglucid; Humans; Methotrexate; Mitomy | 1986 |
Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Human | 1987 |
[Metastasizing primary duodenal cancer. Extended remission in a patient following chemotherapy].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality T | 1986 |
Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma.
Topics: Aged; Chromatography, High Pressure Liquid; Colonic Neoplasms; Half-Life; Humans; Kidney; Kinetics; | 1987 |
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug E | 1987 |
Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubici | 1987 |
Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe | 1987 |
A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix.
Topics: Animals; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Evaluation, Preclinical; Female; Leuke | 1987 |
[Chemotherapy and enteral nutrition in stomach cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1988 |
Spontaneous sister chromatid exchange in metastatic variants of the murine B16 melanoma and human astrocytomas in culture.
Topics: Animals; Astrocytoma; Ethyl Methanesulfonate; Humans; Melanoma, Experimental; Mice; Mitomycin; Mitom | 1988 |
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos | 1988 |
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Wei | 1986 |
Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1986 |
Effects of total-body hyperthermia on metastases from experimental mouse tumors.
Topics: Animals; Cisplatin; Hyperthermia, Induced; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, I | 1985 |
Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1985 |
Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
Topics: Animals; Cell Division; Cytotoxicity, Immunologic; Immunity, Cellular; Melphalan; Mice; Mitomycin; M | 1985 |
[Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1985 |
Mitomycin C and vinblastine in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middl | 1985 |
[A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug | 1985 |